Molecular Targets in Advanced Therapeutics of Cancers: The Role of Pharmacogenetics

Area of Science:

• Oncology
• Pharmacogenomics
• Molecular Biology

Background:

• Advanced molecular targeted therapy improves cancer prognoses but causes adverse effects and variable responses.
• Inter-individual variability in drug response is linked to patient genetic variations.
• Pharmacogenetics offers a pathway to predict treatment efficacy and personalize cancer care.

Purpose of the Study:

• To review established and potential molecular targets for targeted cancer therapy.
• To explore the role of genetic biomarkers in predicting patient responses to targeted therapy.
• To discuss challenges in integrating pharmacogenetic findings into clinical practice for personalized medicine.

Main Methods:

• Literature review of established and emerging molecular targets in targeted cancer therapy.
• Analysis of pharmacogenetics studies investigating genetic biomarkers for treatment response prediction.
• Synthesis of current evidence on the clinical utility and challenges of personalized targeted therapy.

Main Results:

• Molecular targeted therapies have shown significant success but are limited by adverse effects and patient-specific responses.
• Genetic variations in patients contribute to inter-individual differences in drug efficacy and toxicity.
• Numerous molecular targets and associated genetic biomarkers have been identified, with varying degrees of clinical validation.

Conclusions:

• Pharmacogenetic biomarker identification holds promise for individualizing targeted cancer therapy.
• Clinical integration of these biomarkers into personalized medicine faces challenges requiring further validation and research.
• Continued research is essential to refine targeted therapies and develop novel approaches for improved cancer treatment.